Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zogenix nets $60.7m for Zohydro and Sumavel plus debt repayment

This article was originally published in Scrip

Executive Summary

Zogenix, a pharmaceutical company focused on central nervous system disorders and pain, priced 32.5 million shares of common stock plus warrants at $2 per share on 24 July for net proceeds of $60.7 million to finance operations related to the approval and commercialization of the oral extended-release hydrocodone therapy Zohydro, among other expenses.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC018245

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel